600 related articles for article (PubMed ID: 24107281)
21. Aliskiren: the first direct renin inhibitor available for clinical use.
Morganti A; Lonati C
J Nephrol; 2011; 24(5):541-9. PubMed ID: 21786226
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction.
Ito S; Nakura N; Le Breton S; Keefe D
Hypertens Res; 2010 Jan; 33(1):62-6. PubMed ID: 19927154
[TBL] [Abstract][Full Text] [Related]
23. [Renin inhibition in hypertension].
Güleç S
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():15-22. PubMed ID: 20019472
[TBL] [Abstract][Full Text] [Related]
24. Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
Hypertension; 2011 Apr; 57(4):852-8. PubMed ID: 21321303
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.
Gradman AH; Weir MR; Wright M; Bush CA; Keefe DL
J Hum Hypertens; 2010 Nov; 24(11):721-9. PubMed ID: 20200550
[TBL] [Abstract][Full Text] [Related]
26. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
[TBL] [Abstract][Full Text] [Related]
27. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
28. Aliskiren, a direct renin inhibitor, improves vascular endothelial function in patients on hemodialysis independent of antihypertensive effect ∼ a pilot study∼.
Moriya H; Kobayashi S; Ohtake T; Tutumi D; Mochida Y; Ishioka K; Oka M; Maesato K; Hidaka S; Nomura S
Kidney Blood Press Res; 2013; 37(2-3):190-8. PubMed ID: 23736778
[TBL] [Abstract][Full Text] [Related]
29. [Renin inhibition and the kidney].
Ecder T
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
[TBL] [Abstract][Full Text] [Related]
30. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
[TBL] [Abstract][Full Text] [Related]
31. Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury--beyond the direct renin inhibition.
Sun CY; Cherng WJ; Jian HZ; Hsu HH; Wu IW; Hsu HJ; Wu MS
Hypertens Res; 2012 Mar; 35(3):304-11. PubMed ID: 22089535
[TBL] [Abstract][Full Text] [Related]
32. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Sato A; Fukuda S
Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
[TBL] [Abstract][Full Text] [Related]
33. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
34. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Fraune C; Lange S; Krebs C; Hölzel A; Baucke J; Divac N; Schwedhelm E; Streichert T; Velden J; Garrelds IM; Danser AH; Frenay AR; van Goor H; Jankowski V; Stahl R; Nguyen G; Wenzel UO
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Gradman AH; Traub D
Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
[TBL] [Abstract][Full Text] [Related]
37. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
39. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
[TBL] [Abstract][Full Text] [Related]
40. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
